Clinical Trial Update: Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on prasugrel in acute coronary syndrome assessing vasoactive and anti-inflammatory effects. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Unstable Angina

Drugs mentioned

• EFFIENT (prasugrel hydrochloride)

Snippet

Sponsor: University of Cologne | Conditions: Acute Coronary Syndrome, Unstable Angina | Phase 3 | Status: COMPLETED